This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Dykes, D. J. Articles by Montgomery, J. A. Search for Related Content PubMed PubMed Citation Articles by Dykes, D. J. Articles by Montgomery, J. A.

Antitumor Activity of 2-Chloroethyl (Methylsulfonyl)methanesulfonate (Clomesone, NSC 338947) against Selected Tumor Systems in Mice¹

Southern Research Institute, Birmingham, Alabama 35255-5305

Clomesone was evaluated for antitumor activity against a spectrum of animal tumor models. Clomesone exhibited significant antitumor activity against the murine L1210 leukemia implanted i.p., s.c., and intracerebrally (i.c.). Activity against s.c.-implanted tumor was largely independent of schedule and route of administration. Therapeutically optimal single-dose treatment (for tumored mice) was less toxic to nontumored mice than therapeutically optimal prolonged treatment. Clomesone also exhibited activity against other murine tumors (P388 leukemia, B16 melanoma, Lewis lung carcinoma, and M5076 sarcoma). It was active against P388 leukemia sublines resistant to cyclophosphamide, L-phenylalanine mustard, and cis-diamminedichloroplatinum(II). No activity was observed against a P388 subline resistant to N,N'-bis(2-chloroethyl)-N-nitrosourea or against Ridgway osteogenic sarcoma, a nitrosourea-resistant murine solid tumor. Clomesone is generally as effective as the chloroethyl-nitrosoureas against experimental tumor models. Since clomesone does not have the hydroxyethylating and carbamoylating activities of the chloroethylnitrosoureas (which do not appear to contribute to antitumor activity), it would likely be a more toxicologically selective compound. It may prove to be less carcinogenic than the chloroethylnitrosoureas, and it may contribute less target organ toxicity and less interference with the actions of other drugs when used in combinations.

¹ This work was supported in part by Grant PO1-CA-34200 and Contracts NO1-CM-37552 and NO1-CM-47580 from the National Cancer Institute, Department of Health and Human Services.

² To whom requests for reprints should be addressed, at Southern Research Institute, P.O. Box 55305, Birmingham, AL 35255-5305.

Received 8/17/88. Revised 11/28/88. Accepted 12/ 6/88.